Our Tests


Also known as: EGFR Amplification FISH

« Back to test list


Amplification of the EGFR gene, leading to overexpression, can occur in a number of tumour types. This test has diagnostic and prognostic implications in patients with glial tumours.

Clinical Utility

EGFR amplification is currently most clinically useful in brain malignancies of glial origin where it can assist in classification of the tumour. EGFR amplification is a marker of more aggressive disease, but there is conflicting evidence regarding the utility of this association.

Although EGFR amplification can occur in lung tumours, it does not currently have clinical utility in these tumours, as opposed to EGFR mutation testing (see EGFR Screen).

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.



Test Method

Fluorescent in situ hybridisation (FISH) analysis, using probes to enumerate the EGFR gene.

Test Ordering

This test is usually requested by an oncologist.

Formalin fixed, paraffin-embedded tissue (FFPE) – 10 sections of 4 uM thickness, dried overnight at 37 degrees onto charged/coated slides.


Pricing note:

The price varies according to the specific clinical conditions for a particular patient. Please contact Sonic Genetics on 1800 010 447 for more information.

Medicare Rebate

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Turnaround Time

2 working days.

For Doctors